Zobrazeno 1 - 10
of 296
pro vyhledávání: '"Olaf H. Klungel"'
Autor:
Rick A. Vreman, Lourens T. Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E. van der Elst, Hubert GM Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel-Teeuwisse
Publikováno v:
International Journal of Health Policy and Management, Vol 11, Iss 5, Pp 642-650 (2022)
BackgroundThe European Medicines Agency (EMA) aims to resolve uncertainties associated with conditionally approved drugs by imposing post-approval studies. Results from these studies may be relevant for health technology assessment (HTA) organization
Externí odkaz:
https://doaj.org/article/b08a5601b3234a34901de533ff590f12
Autor:
Sophie H. Bots, Judit Riera-Arnau, Svetlana V. Belitser, Davide Messina, Maria Aragón, Ema Alsina, Ian J. Douglas, Carlos E. Durán, Patricia García-Poza, Rosa Gini, Ron M. C. Herings, Consuelo Huerta, Malede Mequanent Sisay, Mar Martín-Pérez, Ivonne Martin, Jetty A. Overbeek, Olga Paoletti, Meritxell Pallejà-Millán, Anna Schultze, Patrick Souverein, Karin M. A. Swart, Felipe Villalobos, Olaf H. Klungel, Miriam C. J. M. Sturkenboom
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary widely across studies due to scarcity of events, especially in age- and sex-stratified analyses.Methods: Population-based cohort study with nested self
Externí odkaz:
https://doaj.org/article/8e3f1c33faf74393a67733a9b72936ef
Autor:
Lourens T. Bloem, Rick A. Vreman, Niels W. L. Peeters, Jarno Hoekman, Menno E. van derElst, Hubert G. M. Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel‐Teeuwisse
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1566-1577 (2021)
Abstract We aimed to determine whether uncertainties identified by the European Medicines Agency (EMA) were associated with negative relative effectiveness assessments (REAs) and negative overall reimbursement recommendations by national health techn
Externí odkaz:
https://doaj.org/article/a2e8481c77804dc8b050c8e96f840417
Autor:
Christine M. Cramer-van der Welle, Marjon V. Verschueren, Merel Tonn, Bas J. M. Peters, Franz M. N. H. Schramel, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde, The Santeon NSCLC Study Group
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients
Externí odkaz:
https://doaj.org/article/7d32e5f6f02144ce9a5f775eb813f943
Autor:
Shifteh Abedian, Ali Abbasi, Anthonius de Boer, Bruno H. Stricker, Stephan J. L. Bakker, Pim van der Harst, Sanaz Sedaghat, Maryam Darvishian, M. Arfan Ikram, Gerjan Navis, Abbas Dehghan, Ido Pen, Ronald P. Stolk, Harold Snieder, Olaf H. Klungel, Patrick Souverein, Behrooz Z. Alizadeh
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Underlying genetic determinants contribute to developing type 2 diabetes (T2D) future diseases. The present study aimed to identify which genetic variants are associated with the incident of the major T2D co-morbid disease. First, we conduct
Externí odkaz:
https://doaj.org/article/aa3f7f248dec47f8937274ca6bd7824b
Increasing the information provided by probabilistic sensitivity analysis: The relative density plot
Autor:
Joost W. Geenen, Rick A. Vreman, Cornelis Boersma, Olaf H. Klungel, Anke M. Hövels, Renske M. T. Ten Ham
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-10 (2020)
Abstract Background Results of probabilistic sensitivity analyses (PSA) are frequently visualized as a scatterplot, which is limited through overdrawing and a lack of insight in relative density. To overcome these limitations, we have developed the R
Externí odkaz:
https://doaj.org/article/2553ae0e6ad6472c8c4eede77ea9540f
Autor:
Anne H. Tavenier, Renicus S. Hermanides, Jan Paul Ottervanger, Svetlana V. Belitser, Olaf H. Klungel, Yolande Appelman, Maarten A.H. van Leeuwen, Arnoud W.J. van 't Hof
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Background: Fast and adequate platelet inhibition is one of the cornerstones in the treatment of patients with ST-elevation myocardial infarction (STEMI). The aim of this analysis is to examine sex differences in platelet inhibition in the acute trea
Externí odkaz:
https://doaj.org/article/43c39086d6d54636adad018968b1421c
Autor:
Renske M.T. ten Ham, Jarno Hoekman, Anke M. Hövels, Andre W. Broekmans, Hubert G.M. Leufkens, Olaf H. Klungel
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 11, Iss , Pp 121-130 (2018)
Advanced therapy medicinal products (ATMPs) hold promise as treatments for previously untreatable and high-burden diseases. Expectations are high and active company pipelines are observed, yet only 10 market authorizations were approved in Europe. Ou
Externí odkaz:
https://doaj.org/article/d1e10b2078114479a61d2de16d64634b
Autor:
Amr Makady, Rachel R. J. Kalf, Bettina Ryll, Gilliosa Spurrier, Anthonius de Boer, Hans Hillege, Olaf H. Klungel, Wim Goettsch, on behalf of GetReal Workpackage
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Purpose Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in overall survival amongst innovative products may be difficult to measure in clinical trials, and their use may be associated with increased toxic
Externí odkaz:
https://doaj.org/article/2c67055283bb4b4c996717863548558a
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background: In many countries, Budget Impact (BI) informs reimbursement decisions. Evidence has shown that decision-makers have restricted access based on high BI estimates but studies show that BI estimates are often inaccurate. Objective: To assess
Externí odkaz:
https://doaj.org/article/31bee768a57a4f7b81d61f585da3c894